July 23, 2009 (FinancialWire) — Orexigen Therapeutics, Inc. (NASDAQ: OREX) plans to offer nine million shares of its common stock in an underwritten public offering. Leerink Swann is acting as sole book-running manager.

In connection with this offering, Orexigen plans to grant to the underwriter a 30-day option to purchase up to an additional 1.35 million shares of common stock to cover overallotments.

Orexigen is offering all of the shares.

San Diego-based Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The company’s lead investigational product, Contrave, has completed Phase 3 clinical trials. The company said the drug is on track for a regulatory submission with the FDA in the first half of 2010.

Orexigen’s second product, Empatic, is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.